Your browser is no longer supported. Please, upgrade your browser.
Settings
AKAO Achaogen, Inc. daily Stock Chart
AKAO [NASD]
Achaogen, Inc.
Index- P/E- EPS (ttm)-3.74 Insider Own1.20% Shs Outstand53.24M Perf Week-38.84%
Market Cap106.48M Forward P/E- EPS next Y-1.96 Insider Trans-1.58% Shs Float33.47M Perf Month-46.24%
Income-163.50M PEG- EPS next Q-0.76 Inst Own65.50% Short Float24.20% Perf Quarter-64.60%
Sales7.20M P/S14.79 EPS this Y-5.50% Inst Trans0.53% Short Ratio10.15 Perf Half Y-84.46%
Book/sh0.55 P/B3.64 EPS next Y41.80% ROA-113.10% Target Price14.22 Perf Year-86.35%
Cash/sh1.09 P/C1.83 EPS next 5Y- ROE-227.20% 52W Range2.10 - 15.00 Perf YTD-81.38%
Dividend- P/FCF- EPS past 5Y-22.20% ROI-82.00% 52W High-86.67% Beta0.47
Dividend %- Quick Ratio2.50 Sales past 5Y-9.00% Gross Margin- 52W Low-4.77% ATR0.38
Employees234 Current Ratio2.50 Sales Q/Q233.30% Oper. Margin- RSI (14)19.12 Volatility21.10% 11.79%
OptionableYes Debt/Eq1.40 EPS Q/Q-30.30% Profit Margin- Rel Volume1.97 Prev Close2.25
ShortableYes LT Debt/Eq1.40 EarningsNov 08 BMO Payout- Avg Volume797.46K Price2.00
Recom2.00 SMA20-46.26% SMA50-51.52% SMA200-77.28% Volume1,570,643 Change-11.11%
Nov-12-18Downgrade Wedbush Outperform → Neutral $17 → $3
Nov-12-18Downgrade H.C. Wainwright Buy → Neutral $19 → $3
Nov-09-18Downgrade Stifel Buy → Hold
Nov-09-18Downgrade Mizuho Buy → Neutral
Nov-09-18Downgrade Gabelli & Co Buy → Hold
Aug-07-18Reiterated Stifel Buy $14 → $22
Aug-07-18Downgrade Needham Buy → Hold
Mar-01-18Reiterated H.C. Wainwright Buy $31 → $29
Feb-28-18Reiterated Needham Buy $29 → $20
Feb-07-18Reiterated H.C. Wainwright Buy $25 → $31
Nov-09-17Reiterated Stifel Buy $30 → $27
Oct-09-17Reiterated Leerink Partners Outperform $28 → $22
Jun-15-17Initiated H.C. Wainwright Buy $29
May-09-17Reiterated Stifel Buy $28 → $31
Mar-15-17Reiterated Stifel Buy $27 → $28
Mar-06-17Reiterated Wedbush Outperform $23 → $28
Mar-02-17Reiterated Needham Buy $19 → $29
Feb-07-17Initiated Stifel Buy $27
Feb-01-17Reiterated Wedbush Outperform $19 → $23
Jan-04-17Initiated Leerink Partners Outperform
Nov-09-18 08:01AM  Achaogen Announces Presentations at Two Investor Healthcare Conferences in November GlobeNewswire -15.09%
Nov-08-18 05:17PM  Edited Transcript of AKAO earnings conference call or presentation 8-Nov-18 1:30pm GMT Thomson Reuters StreetEvents -13.96%
09:15AM  Achaogen (AKAO) Reports Q3 Loss, Misses Revenue Estimates Zacks
08:10AM  Achaogen: 3Q Earnings Snapshot Associated Press
08:01AM  Achaogen Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-05-18 05:16PM  4 months after drug approval, Achaogen eyes fire sale American City Business Journals -12.57%
09:01AM  Achaogen Announces Review of Strategic Alternatives and Corporate Restructuring GlobeNewswire
Nov-02-18 08:01AM  Achaogen to Host Conference Call and Webcast of Third Quarter 2018 Financial Results on November 8, 2018 GlobeNewswire
Oct-29-18 08:55AM  Consolidated Research: 2018 Summary Expectations for Insys Therapeutics, Achaogen, Astec Industries, Central European Media Enterprises, Pzena Investment Management, and Clementia Pharmaceuticals Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-17-18 08:01AM  Achaogen Submits Marketing Authorization Application to the European Medicines Agency for Plazomicin GlobeNewswire
Oct-03-18 08:01AM  Achaogen Highlights Multiple Plazomicin Presentations at IDWeek 2018 GlobeNewswire +11.19%
Sep-19-18 08:01AM  Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2018 GlobeNewswire +6.54%
Sep-18-18 08:01AM  Achaogen to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-04-18 04:00AM  Achaogen Highlights Multiple Plazomicin Presentations at ESCMID/ASM 2018 Conference GlobeNewswire
Aug-24-18 08:39AM  Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock? Zacks
Aug-17-18 07:45PM  Edited Transcript of AKAO earnings conference call or presentation 6-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-15-18 07:30AM  Analysis: Positioning to Benefit within Northeast, Hurco Companies, PGT, Bassett Furniture Industries, Insys Therapeutics, and Achaogen Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-13-18 04:01PM  Achaogen to Present at the Wedbush PacGrow Healthcare Conference GlobeNewswire -6.28%
Aug-07-18 05:45PM  [$$] Drug Company Achaogen Expresses Doubt About Its Viability The Wall Street Journal
07:13AM  New Strong Sell Stocks for August 7th Zacks
Aug-06-18 06:10PM  Achaogen (AKAO) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:04PM  Achaogen: 2Q Earnings Snapshot Associated Press
04:01PM  Achaogen Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM  Achaogen, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-18 08:00AM  CMS Grants New Technology Add-on Payment to ZEMDRI (plazomicin) GlobeNewswire
Jul-27-18 04:34PM  Antibiotics market wipes out 80 jobs at Peninsula company a month after its 1st drug approval American City Business Journals
08:44AM  Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter Benzinga
Jul-26-18 04:01PM  Achaogen Announces Strategic Update to Align Operations with Commercial and Clinical Development Priorities GlobeNewswire
03:47PM  A guide to biotechs building boom in South City American City Business Journals
Jul-24-18 08:01AM  Achaogen to Host Conference Call and Webcast of Second Quarter 2018 Financial Results on August 6, 2018 GlobeNewswire
Jul-20-18 08:00AM  Achaogen Launches ZEMDRI (plazomicin), a Once-Daily Aminoglycoside for use in complicated Urinary Tract Infections (cUTI) GlobeNewswire
Jul-19-18 07:45AM  Breakfast Technical Briefing on Avid Bioservices and Three Other Additional Biotech Stocks ACCESSWIRE
Jul-10-18 05:17PM  Achaogen to Host Investor Lunch Updating Investors on Commercial Strategy Post FDA Approval of Plazomicin on July 12th in New York City GlobeNewswire
Jun-27-18 08:00AM  Todays Research Reports on Stocks to Watch: Achaogen and Avinger ACCESSWIRE -6.99%
Jun-26-18 04:32PM  Why Hertz Global Holdings, Sibanye-Stillwater, and Achaogen Slumped Today Motley Fool -20.22%
01:07PM  A Mixed-Bag Decision Causes Achaogen's 24% Tumble Motley Fool
08:57AM  FDA Approves Achaogen's Antibiotic For Urinary Tract Infection, But Issues CRL For Bloodstream Infections Benzinga
08:43AM  Achaogen stock slides 11% premarket after FDA declines to approve treatment for bloodstream infection MarketWatch
08:33AM  UPDATE -- ZEMDRI (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI) GlobeNewswire
08:30AM  Achaogen's antibiotic gets FDA nod for urinary tract infections Reuters
08:00AM  ZEMDRITM (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI) GlobeNewswire
08:00AM  Today's Research Reports on Trending Tickers: Sophiris Bio and Achaogen ACCESSWIRE
Jun-25-18 09:29AM  Options Traders Expect Huge Moves in Achaogen (AKAO) Stock Zacks
Jun-22-18 04:16PM  Achaogen In The Spotlight Ahead of FDA Verdict On Plazomicin Benzinga
Jun-20-18 08:45AM  Why Did Achaogen Incs (NASDAQ:AKAO) Insiders Buy Up More Shares? Simply Wall St. +6.63%
Jun-11-18 08:01AM  Achaogen Highlights Multiple Plazomicin Presentations at ASM Microbe 2018 Annual Meeting GlobeNewswire
Jun-08-18 09:14AM  An Unlikely Biotech Investor: The Government Forbes
Jun-01-18 07:20AM  Stock Performance Review on ACADIA Pharma and Three Other Biotech Stocks ACCESSWIRE
May-24-18 08:01AM  Achaogen Announces Multiple Plazomicin Presentations at ASM Microbe 2018 Annual Meeting GlobeNewswire
May-09-18 01:45AM  Edited Transcript of AKAO earnings conference call or presentation 4-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-08-18 07:50AM  Blog Exposure - Lexicon Pharmas New XERMELO(R) (Telotristat Ethyl) Data Published in Clinical Therapeutics ACCESSWIRE +5.40%
May-04-18 07:56AM  Achaogen: 1Q Earnings Snapshot Associated Press +5.88%
07:30AM  Achaogen Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
06:15AM  Achaogen, Inc. to Host Earnings Call ACCESSWIRE
May-03-18 11:03AM  Why Achaogen Shares Are Getting Crushed On Plazomicin FDA News Benzinga -24.76%
09:31AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:31AM  Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss Benzinga
07:30AM  Why the Prestigious Mayo Clinic is a 10% Holder of This Undiscovered Public Company ACCESSWIRE
May-02-18 08:17PM  Peninsula drug developer's stock plunges, but its antibiotic still could win FDA approval American City Business Journals
05:12PM  Achaogen Announces FDA Advisory Committee Voted Unanimously in Favor of Plazomicin for Treatment of Adults with Complicated Urinary Tract Infections GlobeNewswire
07:40AM  Market Trends Toward New Normal in Cohen & Steers, Achaogen, Ares Commercial Real Estate, CONMED, Marcus, and First Defiance Financial Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
07:05AM  Achaogen Stock Trading Halted Today GlobeNewswire
Apr-30-18 10:54AM  Watch Out for These Pharmaceutical Players Racing Toward FDA Approvals SmarterAnalyst +9.32%
08:37AM  Options Traders Expect Huge Moves in Achaogen (AKAO) Stock Zacks
Apr-26-18 08:01AM  Achaogen Wins CARB-X Funding Award to Advance Development of Novel Aminoglycoside to Fight Highly-Resistant Infections GlobeNewswire
Apr-25-18 08:01AM  Achaogen to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 4, 2018 GlobeNewswire
Apr-23-18 08:01AM  Achaogen Highlights Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) GlobeNewswire
Apr-10-18 08:01AM  Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) GlobeNewswire
Apr-06-18 11:19AM  Peninsula anti-aging drug company files for $85M IPO American City Business Journals
Apr-04-18 01:00PM  [$$] A Billionaire's Latest Biotech Bet Barrons.com
Mar-30-18 03:26PM  Edited Transcript of AKAO earnings conference call or presentation 27-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-26-18 02:18PM  7 Well-Known Stocks That Are Set to Reverse Direction TheStreet.com
Mar-25-18 09:00AM  2 Small Biotechs That Continue to Look Good TheStreet.com
Mar-22-18 08:01AM  Achaogen Announces New Employment Inducement Grants GlobeNewswire +5.45%
Mar-21-18 08:00AM  Achaogen Announces Date of FDA Advisory Committee Meeting for Plazomicin GlobeNewswire +13.45%
Mar-14-18 08:01AM  Achaogen to Present at Needham & Companys 17th Annual Healthcare Conference GlobeNewswire
Mar-08-18 07:30AM  Wired News Cellectar Biosciences to Present Results from Phase-1 Study of CLR 124 Uptake in Brain Tumors at the World Congress of the World Federation of Nuclear Medicine and Biology ACCESSWIRE
Mar-06-18 08:01AM  Achaogen to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-05-18 10:51AM  When Can We Expect A Profit From Achaogen Inc (NASDAQ:AKAO)? Simply Wall St.
Mar-02-18 08:15AM  Report: Exploring Fundamental Drivers Behind Accelerate Diagnostics, FTI Consulting, Spark Therapeutics, Achaogen, Oxford Industries, and Kronos Worldwide New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-01-18 09:01AM  Achaogen Enters Into New $50 Million Secured Credit Facility with Silicon Valley Bank PR Newswire
Feb-27-18 07:11PM  Achaogen reports 4Q loss Associated Press
04:01PM  Achaogen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
12:20PM  Achaogen, Inc. to Host Earnings Call ACCESSWIRE
Feb-21-18 04:01PM  Achaogen Announces New Employment Inducement Grants GlobeNewswire
Feb-13-18 08:01AM  Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2017 Financial Results on February 27, 2018 GlobeNewswire
Feb-07-18 08:01AM  Achaogen to Present at the Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Feb-01-18 08:05AM  Achaogen, Plazomicin NDA's Upcoming PDUFA Review and the Change to VAI Status ACCESSWIRE
Jan-31-18 09:14AM  Heres Whats Moving Bellicum Pharmaceuticals And Achaogen Market Exclusive -9.86%
Jan-30-18 01:45PM  Here's Why Achaogen Inc Rose as Much as 16.9% Today Motley Fool +10.04%
10:07AM  Achaogen Announces Upgraded Status for Plazomicin Fill Manufacturer GlobeNewswire
Jan-25-18 08:00AM  Achaogen Announces New Employment Inducement Grants GlobeNewswire
Jan-08-18 08:05AM  Report: Developing Opportunities within Kronos Worldwide, Emerge Energy Services LP, Achaogen, Ameris, Forward Air, and Northwest Bancshares Future Expectations, Projections Moving into 2018 GlobeNewswire
Jan-06-18 10:24AM  3 Small-Cap Biotech Stocks With Major Catalysts in 2018 Motley Fool
Jan-03-18 04:01PM  Achaogen to Present at J.P. Morgan Healthcare Conference GlobeNewswire -5.36%
09:55AM  Achaogen's NDA for Plazomicin Gets Priority Review From FDA Zacks
Jan-02-18 11:03AM  Achaogen stock surges 3% after FDA plans to review its UTI therapy MarketWatch
08:49AM  What Should We Expect From Achaogen Incs (NASDAQ:AKAO) Earnings In The Years Ahead? Simply Wall St.
08:01AM  Achaogen Announces Positive Top-Line Results from First Clinical Trial of Orally-Administered Antibacterial Candidate C-Scape GlobeNewswire
08:01AM  Achaogen Announces FDA Acceptance of New Drug Application with Priority Review for Plazomicin for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections GlobeNewswire
Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LOEB GARYGeneral CounselSep 25Sale4.151,0384,30822,831Sep 27 08:08 PM
Wise BlakeChief Operating OfficerSep 25Sale4.153,24213,45492,721Sep 27 08:07 PM
Hillan Kenneth J.See RemarksJun 28Option Exercise6.10177,9351,084,807293,336Jun 29 08:33 PM
Wise BlakeChief Executive OfficerJun 26Sale9.591,19411,45095,963Jun 28 04:21 PM
Schilke TobinChief Financial OfficerJun 26Sale9.592982,85847,748Jun 28 04:20 PM
LOEB GARYGeneral CounselJun 26Sale9.593243,10723,869Jun 28 04:20 PM
Hillan Kenneth J.See RemarksJun 26Sale9.597447,135115,401Jun 28 04:19 PM
Dorling JanetChief Commercial OfficerJun 26Sale9.594504,31623,819Jun 28 04:18 PM
Schilke TobinChief Financial OfficerJun 11Sale11.952,08724,94047,186Jun 13 05:03 PM
DUGGAN ROBERT W10% OwnerMay 03Buy11.46130,2551,492,654100,255May 07 05:54 PM
DUGGAN ROBERT W10% OwnerMay 03Buy11.31846,6259,579,4778,027,627May 07 05:54 PM
DUGGAN ROBERT W10% OwnerApr 27Buy12.96102,8491,333,1607,181,002Apr 27 06:30 PM
DUGGAN ROBERT W10% OwnerApr 26Buy12.9650,000647,7557,078,153Apr 27 06:30 PM
DUGGAN ROBERT W10% OwnerApr 25Buy13.0277,2471,005,9497,028,153Apr 27 06:30 PM
DUGGAN ROBERT W10% OwnerApr 23Buy13.07132,4871,730,9696,950,906Apr 23 06:50 PM
DUGGAN ROBERT W10% OwnerApr 20Buy13.23216,1502,860,4216,818,419Apr 23 06:50 PM
DUGGAN ROBERT W10% OwnerApr 19Buy12.76119,7001,527,2646,602,269Apr 23 06:50 PM
DUGGAN ROBERT W10% OwnerApr 04Buy12.4447,361588,9776,482,569Apr 04 09:25 PM
DUGGAN ROBERT W10% OwnerApr 03Buy12.4624,100300,2406,435,208Apr 04 09:25 PM
DUGGAN ROBERT W10% OwnerApr 02Buy12.5120,000250,2026,411,108Apr 04 09:25 PM
DUGGAN ROBERT W10% OwnerMar 28Buy12.4430,000373,0956,391,108Mar 30 07:18 PM
DUGGAN ROBERT W10% OwnerMar 20Buy11.0925,000277,1556,361,108Mar 21 06:39 PM
DUGGAN ROBERT W10% OwnerMar 19Buy11.2011,300126,5576,336,108Mar 21 06:39 PM
DUGGAN ROBERT W10% OwnerMar 15Buy11.2330,000336,7566,324,808Mar 16 05:04 PM
DUGGAN ROBERT W10% OwnerMar 14Buy11.5719,660227,4886,294,808Mar 16 05:04 PM
Hillan Kenneth J.See RemarksMar 13Sale11.742,73532,10995,151Mar 15 07:17 PM
DUGGAN ROBERT W10% OwnerMar 12Buy11.3920,000227,8026,275,148Mar 13 06:38 PM
DUGGAN ROBERT W10% OwnerMar 09Buy11.4150,000570,5206,255,148Mar 13 06:38 PM
DUGGAN ROBERT W10% OwnerMar 02Buy10.1496,790981,6836,205,148Mar 02 06:44 PM
DUGGAN ROBERT W10% OwnerMar 01Buy10.33410,6064,243,2856,108,358Mar 02 06:44 PM
DUGGAN ROBERT W10% OwnerFeb 28Buy10.7020,000213,9285,697,752Mar 02 06:44 PM
Swem LeeChief Scientific OfficerFeb 21Sale10.671,28213,67936,819Feb 23 08:38 PM
Wise BlakeChief Executive OfficerFeb 21Sale10.671,64017,49965,645Feb 23 08:39 PM
Schilke TobinChief Financial OfficerFeb 21Sale10.671,10811,82240,185Feb 23 08:38 PM
Hillan Kenneth J.See RemarksFeb 21Sale10.674,60649,14697,886Feb 23 08:37 PM
DUGGAN ROBERT W10% OwnerFeb 14Buy10.969,442103,4875,677,752Feb 15 05:43 PM
DUGGAN ROBERT W10% OwnerFeb 13Buy10.975586,1195,668,310Feb 15 05:43 PM
DUGGAN ROBERT W10% OwnerJan 05Buy11.5150,000575,5005,667,752Jan 05 06:03 PM
DUGGAN ROBERT W10% OwnerJan 03Buy10.8915,000163,3535,617,752Jan 05 06:03 PM
DUGGAN ROBERT W10% OwnerDec 18Buy11.1395,0121,057,4935,602,752Dec 20 06:07 PM